Correlates of Obesity Medication Use in Paediatric Weight Management Programmes: A POWER Consortium Analysis

IF 2.5 3区医学 Q1 PEDIATRICS

Pediatric Obesity Pub Date : 2026-07-05 DOI:10.1111/ijpo.70127

Amy L. Christison, Roy Kim, Eileen King, Rashmi Sahay, Roohi Kharofa, Brooke R. Sweeney, Vidhu Thaker, Jared M. Tucker, Alaina P. Vidmar, Jennifer K. Yee, Shelley Kirk

{"title":"Correlates of Obesity Medication Use in Paediatric Weight Management Programmes: A POWER Consortium Analysis","authors":"Amy L. Christison, Roy Kim, Eileen King, Rashmi Sahay, Roohi Kharofa, Brooke R. Sweeney, Vidhu Thaker, Jared M. Tucker, Alaina P. Vidmar, Jennifer K. Yee, Shelley Kirk","doi":"10.1111/ijpo.70127","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>The national POWER registry of paediatric weight management programmes reported increased obesity medication (ObM) use in recent years. However, factors influencing ObM prescribing are not well understood. This study aimed to compare (1) clinical characteristics between youth prescribed ObMs and those who were not and (2) prescribing patterns among programmes.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Data from youth aged 6–18 years seen at 12 POWER sites between 2018 and 2024 were analysed. Clinical and demographic variables were compared between ObM and non-ObM groups using Fisher's exact test and logistic regression, adjusting for site. Site-level prescribing patterns were assessed using <i>χ</i><sup>2</sup> and Fisher's exact tests.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>ObMs were prescribed to 927 of 4628 (20%) patients. Topiramate (37%) and metformin (43%) were the most prescribed. ObM patients were older [12–15 years aOR (CI) = 1.7 (1.4, 2.0); 16–18 years aOR (CI) = 1.6 (1.3, 2.0) vs. 6–11 years], had more severe obesity [Class 2 aOR (CI) = 1.6 (1.3, 2.2); Class 3 aOR (CI) = 2.9 (2.3, 3.8) vs. Class 1] and had more obesity related co-morbidities, but demographic characteristics were not different. Higher prescribing programmes offered ObMs sooner and multiple ObMs more often.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>ObM prescribing was strongly associated with age, obesity severity and comorbidities, highlighting the need for prospective studies on earlier initiation to prevent disease progression.</p>\n </section>\n </div>","PeriodicalId":217,"journal":{"name":"Pediatric Obesity","volume":"21 7","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2026-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Obesity","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ijpo.70127","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

The national POWER registry of paediatric weight management programmes reported increased obesity medication (ObM) use in recent years. However, factors influencing ObM prescribing are not well understood. This study aimed to compare (1) clinical characteristics between youth prescribed ObMs and those who were not and (2) prescribing patterns among programmes.

Methods

Data from youth aged 6–18 years seen at 12 POWER sites between 2018 and 2024 were analysed. Clinical and demographic variables were compared between ObM and non-ObM groups using Fisher's exact test and logistic regression, adjusting for site. Site-level prescribing patterns were assessed using χ² and Fisher's exact tests.

Results

ObMs were prescribed to 927 of 4628 (20%) patients. Topiramate (37%) and metformin (43%) were the most prescribed. ObM patients were older [12–15 years aOR (CI) = 1.7 (1.4, 2.0); 16–18 years aOR (CI) = 1.6 (1.3, 2.0) vs. 6–11 years], had more severe obesity [Class 2 aOR (CI) = 1.6 (1.3, 2.2); Class 3 aOR (CI) = 2.9 (2.3, 3.8) vs. Class 1] and had more obesity related co-morbidities, but demographic characteristics were not different. Higher prescribing programmes offered ObMs sooner and multiple ObMs more often.

Conclusions

ObM prescribing was strongly associated with age, obesity severity and comorbidities, highlighting the need for prospective studies on earlier initiation to prevent disease progression.

查看原文本刊更多论文

儿童体重管理方案中肥胖药物使用的相关性：POWER联盟分析。

导论：国家儿童体重管理计划的POWER登记报告了近年来肥胖药物（ObM）的使用增加。然而，影响ObM处方的因素尚不清楚。本研究的目的是比较(1)开具处方的青年和未开具处方的青年之间的临床特征，以及(2)各方案之间的处方模式。方法：分析2018年至2024年12个POWER站点6-18岁青少年的数据。采用Fisher精确检验和逻辑回归，根据地点进行调整，比较ObM组和非ObM组的临床和人口统计学变量。采用χ2和Fisher精确检验对基层处方模式进行评估。结果：4628例患者中有927例（20%）使用了ObMs。托吡酯（37%）和二甲双胍（43%）是处方最多的。ObM患者年龄较大[12-15岁aOR (CI) = 1.7 (1.4, 2.0)；16-18岁的aOR (CI) = 1.6 (1.3, 2.0) vs. 6-11岁]，有更严重的肥胖[2级aOR (CI) = 1.6 (1.3, 2.2)；3级aOR （CI) = 2.9 (2.3, 3.8) vs. 1级）并且有更多的肥胖相关合并症，但人口学特征没有差异。更高的处方规划更快地提供obm，更频繁地提供多重obm。结论：ObM处方与年龄、肥胖严重程度和合并症密切相关，强调了早期开始治疗以预防疾病进展的前瞻性研究的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Obesity PEDIATRICS-

CiteScore

7.30

自引率

5.30%

发文量

117

审稿时长

6-12 weeks

期刊介绍： Pediatric Obesity is a peer-reviewed, monthly journal devoted to research into obesity during childhood and adolescence. The topic is currently at the centre of intense interest in the scientific community, and is of increasing concern to health policy-makers and the public at large. Pediatric Obesity has established itself as the leading journal for high quality papers in this field, including, but not limited to, the following: Genetic, molecular, biochemical and physiological aspects of obesity – basic, applied and clinical studies relating to mechanisms of the development of obesity throughout the life course and the consequent effects of obesity on health outcomes Metabolic consequences of child and adolescent obesity Epidemiological and population-based studies of child and adolescent overweight and obesity Measurement and diagnostic issues in assessing child and adolescent adiposity, physical activity and nutrition Clinical management of children and adolescents with obesity including studies of treatment and prevention Co-morbidities linked to child and adolescent obesity – mechanisms, assessment, and treatment Life-cycle factors eg familial, intrauterine and developmental aspects of child and adolescent obesity Nutrition security and the "double burden" of obesity and malnutrition Health promotion strategies around the issues of obesity, nutrition and physical activity in children and adolescents Community and public health measures to prevent overweight and obesity in children and adolescents.